San Francisco Sentry Investment Group CA decreased its stake in shares of Walgreens Boots Alliance Inc. (NASDAQ:WBA) by 0.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 15,143 shares of the pharmacy operator’s stock after selling 65 shares during the period. San Francisco Sentry Investment Group CA’s holdings in Walgreens Boots Alliance were worth $1,261,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the stock. CapWealth Advisors LLC increased its position in Walgreens Boots Alliance by 30.0% in the first quarter. CapWealth Advisors LLC now owns 1,300 shares of the pharmacy operator’s stock valued at $110,000 after buying an additional 300 shares during the last quarter. Kings Point Capital Management increased its position in Walgreens Boots Alliance by 12.8% in the first quarter. Kings Point Capital Management now owns 1,323 shares of the pharmacy operator’s stock valued at $111,000 after buying an additional 150 shares during the last quarter. Jolley Asset Management LLC increased its position in Walgreens Boots Alliance by 104.5% in the second quarter. Jolley Asset Management LLC now owns 1,370 shares of the pharmacy operator’s stock valued at $114,000 after buying an additional 700 shares during the last quarter. MCF Advisors LLC increased its position in Walgreens Boots Alliance by 0.4% in the first quarter. MCF Advisors LLC now owns 1,371 shares of the pharmacy operator’s stock valued at $116,000 after buying an additional 6 shares during the last quarter. Finally, Cribstone Capital Management LLC purchased a new position in Walgreens Boots Alliance during the second quarter valued at $149,000. 59.74% of the stock is owned by hedge funds and other institutional investors.

Shares of Walgreens Boots Alliance Inc. (NASDAQ:WBA) traded down 0.94% during midday trading on Wednesday, hitting $79.88. The stock had a trading volume of 1,626,569 shares. Walgreens Boots Alliance Inc. has a 52-week low of $71.50 and a 52-week high of $95.74. The company’s 50 day moving average is $81.66 and its 200 day moving average is $81.27. The company has a market cap of $86.46 billion, a PE ratio of 27.60 and a beta of 1.01.

Walgreens Boots Alliance (NASDAQ:WBA) last released its quarterly earnings data on Wednesday, July 6th. The pharmacy operator reported $1.18 earnings per share for the quarter, topping analysts’ consensus estimates of $1.14 by $0.04. The firm earned $29.50 billion during the quarter. Walgreens Boots Alliance had a return on equity of 15.56% and a net margin of 2.70%. The business’s revenue was up 2.4% on a year-over-year basis. During the same period last year, the company earned $1.02 EPS. On average, analysts anticipate that Walgreens Boots Alliance Inc. will post $4.51 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which was paid on Monday, September 12th. Stockholders of record on Friday, August 19th were paid a $0.375 dividend. This is a positive change from Walgreens Boots Alliance’s previous quarterly dividend of $0.36. The ex-dividend date was Wednesday, August 17th. This represents a $1.50 dividend on an annualized basis and a dividend yield of 1.86%. Walgreens Boots Alliance’s dividend payout ratio is 51.90%.

WBA has been the subject of several analyst reports. Bank of America Corp. restated a “buy” rating and issued a $78.66 target price (down previously from $94.00) on shares of Walgreens Boots Alliance in a research note on Tuesday, June 7th. Deutsche Bank AG restated a “buy” rating on shares of Walgreens Boots Alliance in a research note on Friday, June 10th. Zacks Investment Research upgraded Walgreens Boots Alliance from a “sell” rating to a “hold” rating in a research note on Tuesday, June 21st. Robert W. Baird restated an “outperform” rating and issued a $98.00 target price on shares of Walgreens Boots Alliance in a research note on Monday, June 27th. Finally, Evercore ISI restated a “buy” rating and issued a $93.00 target price on shares of Walgreens Boots Alliance in a research note on Thursday, July 7th. One analyst has rated the stock with a sell rating, five have given a hold rating and fifteen have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $93.13.

In related news, EVP Kathleen Wilson-Thompson sold 29,695 shares of the stock in a transaction that occurred on Thursday, July 14th. The stock was sold at an average price of $83.00, for a total transaction of $2,464,685.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director William C. Foote sold 2,067 shares of the stock in a transaction that occurred on Tuesday, July 26th. The shares were sold at an average price of $81.35, for a total value of $168,150.45. Following the transaction, the director now directly owns 26,690 shares of the company’s stock, valued at $2,171,231.50. The disclosure for this sale can be found here. 21.10% of the stock is owned by insiders.

About Walgreens Boots Alliance

Walgreens Boots Alliance, Inc (Walgreens Boots Alliance) is a holding company. The Company is a global pharmacy-led, health and wellbeing enterprise. Walgreens Boots Alliance operates through three divisions, including Retail Pharmacy USA, Retail Pharmacy International and Pharmaceutical Wholesale. The Company’s products are marketed under a number of brands, which include No7, the Botanics range, Almus (generic medicines), Boots Pharmaceuticals and Soap & Glory (bathing and beauty brand).

5 Day Chart for NASDAQ:WBA

Want to see what other hedge funds are holding WBA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Walgreens Boots Alliance Inc. (NASDAQ:WBA).

Receive News & Ratings for Walgreens Boots Alliance Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Walgreens Boots Alliance Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.